MétaCan
Menu
Back to cohort
Record W4388182309 · doi:10.1016/j.euo.2023.10.004

Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial

2023· article· en· W4388182309 on OpenAlexaff
Andrew J. Armstrong, Noel W. Clarke, Mototsugu Oya, Giuseppe Procopio, Juliana de Menezes, João Daniel Guedes, Pooja Ghatalia, Franco Nolè, Omar Din, Philipp Spiegelhalder, I. Minčík, Robbert van Alphen, Nicolaas Lumen, Christian Hosius, Diansong Zhou, Laura Barker, Melanie Dujka, Fred Saad

Bibliographic record

VenueEuropean Urology Oncology · 2023
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsCentre Hospitalier de l’Université de Montréal
Fundersnot available
KeywordsOlaparibAbirateroneMedicineProstate cancerPharmacokineticsPharmacologyOncologyInternal medicineDrugAbiraterone acetateUrologyCancerAndrogen deprivation therapyAndrogen receptorChemistry

Abstract

fetched live from OpenAlex

PROpel (NCT03732820) was a positive phase 3 trial that demonstrated a clinically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer. For a subset of PROpel patients, steady-state concentrations of olaparib, abiraterone, and Δ4-abiraterone were measured in blood samples collected before and at several time points after dose administration. The pharmacokinetics (PK) for each drug and metabolite were evaluated to determine whether any clinically relevant drug-drug interactions between olaparib and abiraterone occurred. The results demonstrate that steady-state PK parameters for olaparib and abiraterone in PROpel were comparable with those in monotherapy trials. Abiraterone steady-state exposures were similar between treatment arms. Δ4-Abiraterone had slightly lower steady-state exposures when abiraterone was administered in combination with olaparib. These results are consistent with a previous phase 2 study, supporting the conclusion that no clinically relevant PK-based drug-drug interactions occurred when olaparib and abiraterone were given in combination at their full monotherapy doses.Patient summaryWhen drugs are administered in combination, a key consideration is whether there are any interactions between the drugs that may affect their activity. We analyzed blood concentrations of olaparib and abiraterone in a subset of patients with prostate cancer from the PROpel trial to determine if there were interactions between these two drugs. We found that there was no significant effect on the profile of either drug when they were given together at the same doses used when each drug is given individually.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.218
Threshold uncertainty score0.746

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.207
GPT teacher head0.430
Teacher spread0.222 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Urology OncologySame topicPARP inhibition in cancer therapyFrench-language works237,207